In an era of expanding perioperative approaches for resectable non–small-cell lung cancer, new data demonstrate that dual neoadjuvant immunotherapy targeting PD-1 and LAG-3 is feasible; future analyses may enhance patient selection by identifying immune signatures predictive of response.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sung, H. et al. CA Cancer J. Clin. 71, 209–249 (2021).
The National Lung Screening Trial Research Team. N. Engl. J. Med. 365, 395–409 (2011).
Pignon, J. P. et al. J. Clin. Oncol. 26, 3552–3559 (2008).
Desai, A. P., Adashek, J. J., Reuss, J. E., West, H. J. & Mansfield, A. S. JAMA Oncol. 9, 135–142 (2023).
Sorin, M. et al. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2024.0057 (2024).
Schuler, M. Nat. Med. https://doi.org/10.1038/s41591-024-02965-0 (2024).
Wakelee, H. et al. N. Engl. J. Med. 389, 491–503 (2023).
Forde, P. M. et al. N. Engl. J. Med. 386, 1973–1985 (2022).
Pellini, B. & Chaudhuri, A. A. J. Clin. Oncol. 40, 567–575 (2022).
Mino-Kenudson, M. et al. J. Thorac. Oncol. 17, 1335–1354 (2022).
Skoulidis, F. et al. Cancer Discov. 8, 822–835 (2018).
Qiao, M. et al. J. Thorac. Oncol. 16, 1267–1288 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.D.S. previously served on the speakers’ bureau for Jazz Pharmaceuticals and has served on advisory board for Jazz Pharmaceuticals and AstraZeneca. C.M.L. has served on advisory boards for Amgen, AnHeart, Arrivent, AstraZeneca, Blueprints Medicine, BMS, Boehringer Ingelheim, Cepheid, D2G, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech, Gilead, Guardant, Indupro, Janssen, Medscape, Novartis, Pfizer, Regeneron, Roche, Takeda and Tempus and has also served on a data and safety monitoring board for Janssen (uncompensated).
Rights and permissions
About this article
Cite this article
Shields, M.D., Lovly, C.M. Refining neoadjuvant immunotherapy for resectable lung cancer. Nat Med (2024). https://doi.org/10.1038/s41591-024-03001-x
Published:
DOI: https://doi.org/10.1038/s41591-024-03001-x
